Bharat Immunologicals & Biologicals Corporation Limited reported unaudited earnings results for the third quarter and nine months ended December 31, 2017. For the quarter, the company reported income from operations of INR 44.654 million against INR 240.425 million year ago. Total revenue was INR 48.210 million against INR 243.951 million year ago. Profit before finance cost and exceptional was INR 3.820 million against INR 15.672 million year ago. Profit for the period from continuing operations was INR 4.981 million against INR 22.075 million year ago. Basic and diluted earnings per share were INR 0.12 against INR 0.51 a year ago. For the nine months, the company reported income from operations of INR 131.183 million. Total revenue was INR 140.096 million. Loss before finance cost and exceptional was INR 38.018 million. Loss for the period from continuing operations was INR 38.665 million. Basic and diluted loss per share were INR 0.90.